Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

6.30
-0.0550-0.87%
Volume:220.40K
Turnover:1.38M
Market Cap:287.79M
PE:-3.80
High:6.44
Open:6.38
Low:6.14
Close:6.35
52wk High:23.40
52wk Low:4.05
Shares:45.72M
Float Shares:40.19M
Volume Ratio:0.37
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6560
EPS(LYR):-1.1490
ROE:-120.15%
ROA:-53.40%
PB:2.74
PE(LYR):-5.48

Loading ...

Top Premarket Decliners

MT Newswires Live
·
Jul 11

BUZZ-U.S. STOCKS ON THE MOVE-Levi Strauss, Crypto Stocks, Delta

Reuters
·
Jul 11

Capricor Therapeutics Shares Plunge Premarket on FDA Setback

Dow Jones
·
Jul 11

US FDA declines to approve Capricor's muscle disorder therapy

Reuters
·
Jul 11

BRIEF-Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy

Reuters
·
Jul 11

Capricor Therapeutics Initiated at Buy by B. Riley Securities

Dow Jones
·
Jun 27

Capricor Therapeutics Is Maintained at Buy by Jones Trading

Dow Jones
·
Jun 25

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Reuters
·
Jun 24

BRIEF-Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Reuters
·
Jun 24

Capricor Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Jun 24

Oppenheimer Lowers Capricor Therapeutics Price Target to $22 From $43, Maintains Outperform Rating

MT Newswires Live
·
Jun 23

Capricor Therapeutics Down Over 32%, on Pace for Largest Percent Decrease Since September 2023 -- Data Talk

Dow Jones
·
Jun 21

BUZZ-Capricor Therapeutics slide on report FDA regulator ousted over co's cell therapy

Reuters
·
Jun 21

Capricor Reports Slower Disease Progression in 4-Year Duchenne Study

MT Newswires Live
·
Jun 20

Capricor Therapeutics Price Target Maintained With a $31.00/Share by Roth Capital

Dow Jones
·
Jun 18

Capricor Therapeutics' Becker Muscular Dystrophy Drug Gets Orphan Drug Designation in U.S.

Dow Jones
·
Jun 17

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 13

Capricor Therapeutics' Duchenne Therapy Facility Inspection Completed by FDA

MT Newswires Live
·
Jun 11

Capricor Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
May 27

Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating

MT Newswires Live
·
May 20